Neurocrine Biosciences, Inc.
HealthcareNASDAQ:NBIX · NASDAQ Global Select
-$2.95 today
Vol 1.05M · Avg 1.17M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
14.7%
avg -0.3%
ROIC
10.8%
avg -1.7%
ROA
10.3%
avg -0.8%
Analysis
ROE is currently the strongest return metric at 14.7% versus its period average of -0.3%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kyle W. Gano | President, CEO & Director | $1.95M | — | 53 | $7,799.00 | <0.01% |
Jude Onyia | Chief Scientific Officer | $1.41M | — | 62 | $23,405.00 | 0.02% |
Eiry Wyn Roberts | Strategic Advisor | $1.32M | — | 62 | $35,640.00 | 0.04% |
Matthew C. Abernethy | Chief Financial Officer | $1.31M | — | 46 | $42,808.00 | 0.04% |
Eric S. Benevich | Chief Commercial Officer | $1.19M | — | 61 | $72,153.00 | 0.07% |
Sanjay Keswani MBBS | Chief Medical Officer | $1.01M | — | 55 | $9,634.00 | <0.01% |
Darin Lippoldt | Chief Legal Officer & Corporate Secretary | $921,011.00 | — | 60 | $55,094.00 | 0.05% |
Wylie W. Vale | Co-Founder | $47,000.00 | — | 84 | $7,799.00 | <0.01% |
Lawrence Steinman | Co-Founder of Neurocrine | — | — | 78 | — | — |
Lewis Choi | Chief Information Officer | — | — | — | — | — |
Todd Tushla | Vice President of Investor Relations | — | — | — | — | — |
Julie S. Cooke | Chief Human Resources Officer | — | — | 60 | $59,311.00 | 0.06% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
18
$55.33M
Net Sentiment
$55.33M
Net selling
Most Active
SHERWIN STEPHEN A
5 transactions
1–10 of 18
Analysis
Insiders reported 0 buys worth $0.00 and 18 sells worth $55.33M over the last 12 months. That adds up to net selling of $55.33M. SHERWIN STEPHEN A was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | -28.1% | +45.4% (15yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Recent growth has been strongest in Revenue at -28.1% over three years. Forward estimates point to Revenue at +45.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Viatris Inc.
NASDAQ:VTRS
$19.19B
Hologic, Inc.
HOLX
$16.97B
The Cooper Companies, Inc.
NASDAQ:COO
$13.24B
Smith & Nephew plc
NYSE:SNN
$12.97B
Elanco Animal Health Incorporated
NYSE:ELAN
$12.07B
ICON Public Limited Company
NASDAQ:ICLR
$11.19B
Dr. Reddy's Laboratories Limited
NYSE:RDY
$11.07B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.86B
Universal Health Services, Inc.
NYSE:UHS
$9.17B
Tempus AI, Inc.
NASDAQ:TEM
$8.35B
Who manages NBIX?
Neurocrine Biosciences, Inc. (NBIX) lists 12 active executives. The top listed executive is Eiry Wyn Roberts, Strategic Advisor.
Are NBIX insiders buying or selling?
Recent insider activity shows net selling of $19.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.